Table 2.
In a multivariate analysis of breast cancer cases, the expression of YB-1 was better than HER-2 or ER in predicting reduced BCSS
| Prognostic marker | Patients with reduced BCSS | |
| HR (95% CI) | P value | |
| Nodal status | ||
| Positive versus negative | 2.405 (2.083 to 2.776) | 4.6 × 10-33 |
| Tumor size (cm) | ||
| 2 to 5 | 1.605 (1.387 to 1.859) | 2.8 × 10-10 |
| >5 | 2.269 (1.749 to 2.943) | 2.8 × 10-10 |
| Grade | ||
| III versus II versus I | 1.416 (1.215 to 1.651) | 8.9 × 10-6 |
| Age (years) | ||
| <50 versus = 50 | 1.160 (1.000 to 1.345) | 5.0 × 10-2 |
| ER | ||
| Positive versus negative | 0.816 (0.720 to 0.991) | 3.8 × 10-2 |
| Her-2 | ||
| Positive versus negative | 1.259 (1.052 to 1.506) | 1.2 × 10-2 |
| YB-1 | ||
| Positive versus negative | 1.456 (1.257 to 1.656) | 5.6 × 10-7 |
YB-1 was approximately equal to the power of tumor grade yet not as accurate as tumor size or nodal status in predicting reduced BCSS. BCSS, breast cancer specific survival; CI, confidence interval; ER, estrogen receptor; HER, human epidermal growth factor receptor; HR, hazard ratio; YB-1 = Y-box binding protein-1.